Immunotherapy of the SL2-5 murine lymphoma with natural killer cells and tamoxifen or toremifene

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 77-83

  Baral, Edward ^a   Nagy, Eva ^b   Kangas, Lauri ^c   Berczi, Istvan ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c ORION CORPORATION   (Finland)

Author keywords

Cytotoxicity; Estrogen receptor; IL 2; Immunotherapy; Mouse; NK cells; SL2 5 lymphoma; Tamoxifen; Target cell sensitization; Toremifene

Indexed keywords

CIS TAMOXIFEN CITRATE; ESTRADIOL; ESTROGEN RECEPTOR; INTERLEUKIN 2; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG EFFICACY; IMMUNOTHERAPY; LYMPHOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; TUMOR REGRESSION;

ADOPTIVE TRANSFER; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ESTROGEN ANTAGONISTS; FEMALE; KILLER CELLS, NATURAL; LYMPHOMA; MICE; MICE, INBRED DBA; TAMOXIFEN; TOREMIFENE;

EID: 0031052781     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Pena J and Solana R: Histocompatibility antigens and natural killer susceptibility. Immunol Res 11: 133-40, 1992.
2. Lerner LJ and Jordan VC: Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 50: 4177-4189, 1990.
3. Baral E, Glas U, Rutquist L-E and Skoog L: Adjuvant therapy in postmenopausal patients with operable breast cancer. In: Paterson A, Lees A (eds), Fuuuamental Problems in Breast Cancer. Martinus Nijhoff, 1987, pp 235.
4. Baral E, Nagy E and Berczi I: The effect of tamoxifen on the immune response. In: Tamoxifen: Beyond the Antiestrogen (Kellen JA, ed). Boston, MA, Birkhauser, 1996, pp 137-178.
5. Baral E, Nagy E and Berczi I: Target cells are sensitized for cytotoxic T-lymphocyte-mediated destruction by estradiol and tamoxifen. Int J Cancer 57: 1-5, 1994.
6. Baral E, Nagy E and Berczi I: Enhancement of natural killer cell mediated cytotoxicity by tamoxifen. Cancer 75: 591-599, 1995.
7. Baral E, Nagy E and Berczi I: Modulation of lymphokine-activated killer cell-mediated cytotoxicity by estradiol and tamoxifen. Int J Cancer 65: 1-5, 1996.
8. EORTC Breast Co-operative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer: report of the second EORTC Workshop, held on 16-17 March 1978, The Netherlands Cancer Institute. Eur J Cancer 16: 1513-1515, 1980.
9. Pichon MF and Milgrom E: Characterization and assay of progesterone receptor in human mammary carcinoma. Cancer Res 37: 467-471, 1977.
10. Berczi I, Strausbach P and Sehon AH: Rejection of tumor cells in vitro. Science 180: 1289-1291, 1973.
11. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al: Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. New Engl J Med 313: 1485-1492, 1985.
12. Hellstrom I and Hellstrom KE: Tumor immunology: an overview. Ann NY Acad Sci 690: 24-33, 1993.
13. Screpanti I, Felli MP, Toniato E, Meco D, Martinotti L, Frati L, Santoni A and Gulino A: Enhancement of natural-killer-cell susceptibility of human breast-cancer cells by estradiol and v-Ha-ras oncogene. Int J Cancer 47: 445-449, 1991.